Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06704269 · ClinicalTrials.gov registry record · Phase 1

Study to Assess Safety, Efficacy, and Cellular Kinetics of YTB323 in Generalized Myasthenia Gravis

A Phase 1 study of Generalized Myasthenia Gravis, sponsored by Novartis Pharmaceuticals.

Recruiting
Registry status
Phase 1
Development phase
15
Enrollment target
10
Study locations

NCT06704269 is a Phase 1 study of Generalized Myasthenia Gravis that is actively recruiting participants, run by Novartis Pharmaceuticals. The registered enrollment target is 15 participants, below the 131-participant average among 26 other Generalized Myasthenia Gravis trials with a reported enrollment target (89% lower). The trial reports 10 study locations across 5 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06704269, a Phase 1 study of Generalized Myasthenia Gravis, is actively recruiting participants, sponsored by Novartis Pharmaceuticals.

RECRUITING
Registry status
Phase 1
Development phase
15 participants
Enrollment target
10
Study locations

Study Summary

This is a phase I/II study to assess safety, efficacy, and cellular kinetics of YTB323 in participants with treatment-resistant generalized myasthenia gravis. YTB323 is a Biological CAR-T cell therapy.

Conditions Studied

Generalized Myasthenia Gravis

Interventions

  • GENETIC YTB323

Study Locations (10)

Other

  • Novartis Investigative Site - Bordeaux
  • Novartis Investigative Site - Brest
  • Novartis Investigative Site - Lille
  • Novartis Investigative Site - Chiba
  • Novartis Investigative Site - Kyoto
  • Novartis Investigative Site - London

California

  • Univ Cali Irvine ALS Neuromuscular - Orange

North Carolina

  • Wake Forest Univ School of Medicine - Winston-Salem

Texas

  • Houston Methodist Hospital - Houston

South Yorkshire

  • Novartis Investigative Site - Sheffield

Trial Details

FieldValue
Enrollment Target 15 participants
Start Date 2025-04-22
Est. Completion 2029-10-26
Phase Phase 1

Sponsor

Novartis Pharmaceuticals

1,375 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06704269

The ClinicalTrials.gov registry entry for NCT06704269 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 131-participant average among 26 other Generalized Myasthenia Gravis trials with a reported enrollment target (89% lower). The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Generalized Myasthenia Gravis appearing as the primary indexed condition, and to 1 intervention - of which YTB323 is the first listed.

NCT06704269 reports 10 study locations spanning 5 distinct geographic areas - top geographies include Other, California, North Carolina.

Frequently Asked Questions

What is clinical trial NCT06704269 about?

NCT06704269 is a clinical study titled "Study to Assess Safety, Efficacy, and Cellular Kinetics of YTB323 in Generalized Myasthenia Gravis". This is a phase I/II study to assess safety, efficacy, and cellular kinetics of YTB323 in participants with treatment-resistant generalized myasthenia gravis. YTB323 is a Biological CAR-T cell therapy.

What is the current status of trial NCT06704269?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2025-04-22. Estimated completion is 2029-10-26.

What conditions does trial NCT06704269 study?

This clinical trial studies the following conditions: Generalized Myasthenia Gravis.

What interventions are being tested in trial NCT06704269?

The interventions under investigation include: YTB323 (GENETIC).

Who is sponsoring clinical trial NCT06704269?

This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06704269 being conducted?

This trial has 10 study locations across California, North Carolina, Texas, South Yorkshire. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Generalized Myasthenia Gravis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Generalized Myasthenia Gravis

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.